Related Experiment Video
Updated: Jun 7, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
[Incidence, pathology and clinical course and symptoms of neuroendocrine gastrointestinal tumours]
Birgitte Hartnack Federspiel1, Carsten Palnaes Hansen, Ben Vainer
1Patologiafdelingen, Rigshospitalet, 2100 København Ø, Denmark. birgitte.federspiel@rh.regionh.dk
Abstract:
Gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) are unusual. Their incidence, the different tumour types and growth patterns are described. The tumours should be classified according to the WHO 2000 classification and the Tumour Node Metastasis classification according to guidelines from the European Neuroendocrine Tumour Society. Important parameters are localization, size, hormonal secretion, mitotic index, and proliferation index (Ki-67) of the primary tumour. Patients with GEP NET should be referred to as few centres as possible in order to obtain the highest experience and the greatest understanding of these tumours thereby achieving the capacity to offer patients the best possible treatment and to create optimal conditions for research.
Related Concept Videos
Gastritis II: Pathophysiology
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease III: Crohn's Disease